This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Moons, A. H. M. Articles by Büller, H. R. Search for Related Content PubMed PubMed Citation Articles by Moons, A. H. M. Articles by Büller, H. R.

Recombinant nematode anticoagulant protein c2, an inhibitor of the tissue factor/factor VIIa complex, in patients undergoing elective coronary angioplastyAppendix

Arno H. M. Moons, MD^*,*, Ron J. G. Peters, MD, PhD^*, Nick R. Bijsterveld, MD^*, Jan J. Piek, MD, PhD^*, Martin H. Prins, MD, PhD, George P. Vlasuk, PhD, William E. Rote, PhD and Harry R. Büller, MD, PhD

^* Department of Cardiology, Academic Medical Center, Amsterdam, The Netherlands
Department of Epidemiology and Biostatistics, Academic Medical Center, Amsterdam, The Netherlands
Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
Corvas International, Inc., San Diego, California, USA

View larger version (15K): [in a new window]   Figure 1 Femoral compression time in minutes (median value and interquartile range [IQR]) after sheath removal from the femoral artery. *No clopidogrel administration before percutaneous coronary intervention. The IQR of the 3.5* and 5.0 recombinant nematode anticoagulant protein c2 (rNAPc2) dose groups is from 10 to 10 min. A comparison between the placebo group and each rNAPc2 dose group was made by the Mann-Whitney U test.

View larger version (17K): [in a new window]   Figure 2 Mean values (±SEM) of prothrombin activation fragment 1+2 plasma levels for the placebo and recombinant nematode anticoagulant protein c2 (rNAPc2) dose groups. No clopidogrel treatment before percutaneous coronary intervention. The following statistically significant differences were found between the rNAPc2 dose groups and placebo (Bonferroni-corrected p values, including five comparisons at each time point): *p < 0.05: 3.5 and 3.5 vs. placebo; p < 0.01: 7.5 vs. placebo; **p < 0.05: 5.0 vs. placebo; p < 0.01: 3.5 vs. placebo; p < 0.001: 3.5, 7.5, and 10.0 vs. placebo; ***p < 0.05: 3.5, 3.5, and 5.0 vs. placebo; p < 0.001: 7.5 and 10.0 vs. placebo. Solid diamond = placebo; open square = 3.5 µg/kg; x = 3.5 µg/kg; solid triangle = 5.0 µg/kg; open triangle = 7.5 µg/kg; open circle = 10.0 µg/kg.

View larger version (13K): [in a new window]   Figure 3 Plasma levels of recombinant nematode anticoagulant protein c2 (rNAPc2) in relation to plasma levels of prothrombin activation fragment 1+2 (F1+2) at 36 h.